Cogent Biosciences, Inc. (COGT)

Cogent Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	-	7.87
Revenue Growth (YoY)	-	-	-	-	-	-65.02%
Cost of Revenue	-	-	-	-	-	25.74
Gross Profit	-	-	-	-	-	-17.87
Selling, General & Admin	45.49	43.28	34.38	26.21	19.64	17.42
Research & Development	242.98	232.66	173.76	121.63	55.91	-
Operating Expenses	288.47	275.94	208.13	147.84	75.55	17.42
Operating Income	-288.47	-275.94	-208.13	-147.84	-75.55	-35.29
Interest & Investment Income	16.98	18.09	13.08	3.99	0.47	0.14
Other Non Operating Income (Expenses)	1.99	1.99	2.64	3.61	2.81	-0.25
EBT Excluding Unusual Items	-269.5	-255.86	-192.41	-140.24	-72.27	-35.39
Gain (Loss) on Sale of Assets	-	-	-	-	-	7.49
Pretax Income	-269.5	-255.86	-192.41	-140.24	-72.27	-74.81
Earnings From Continuing Operations	-	-255.86	-192.41	-140.24	-72.27	-74.81
Net Income	-269.5	-255.86	-192.41	-140.24	-72.27	-74.81
Preferred Dividends & Other Adjustments	-	-	-	-	-	104.4
Net Income to Common	-269.5	-255.86	-192.41	-140.24	-72.27	-179.21
Shares Outstanding (Basic)	132	104	80	59	39	11
Shares Outstanding (Diluted)	132	104	80	59	39	11
Shares Change (YoY)	113.08%	30.36%	35.54%	51.89%	249.52%	45.42%
EPS (Basic)	-2.04	-2.46	-2.41	-2.38	-1.87	-16.17
EPS (Diluted)	-2.04	-2.46	-2.41	-2.38	-1.87	-16.17
Free Cash Flow	-222.82	-208.36	-156.42	-125.5	-60.48	-35.85
Free Cash Flow Per Share	-1.69	-2.00	-1.96	-2.13	-1.56	-3.23
Gross Margin	-	-	-	-	-	-227.00%
Operating Margin	-	-	-	-	-	-448.34%
Profit Margin	-	-	-	-	-	-2276.81%
Free Cash Flow Margin	-	-	-	-	-	-455.47%
EBITDA	-285.98	-273.49	-205.86	-147	-75.4	-34.57
D&A For EBITDA	2.49	2.45	2.27	0.84	0.15	0.72
EBIT	-288.47	-275.94	-208.13	-147.84	-75.55	-35.29

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q